Should You Hold Synthroid for a TSH of 0.0?
You should reduce the levothyroxine dose, not completely hold it, when TSH is suppressed to 0.0 mIU/L in patients being treated for hypothyroidism without thyroid cancer or nodules. Complete discontinuation risks precipitating symptomatic hypothyroidism.
Clinical Context Matters
The appropriate action depends critically on why the patient is taking levothyroxine:
For Hypothyroidism (No Cancer/Nodules)
When TSH is <0.1 mIU/L in a patient taking levothyroxine for hypothyroidism, the dose should be decreased to allow TSH to rise toward the reference range 1. The 2004 JAMA guidelines are explicit: review the indication for therapy and reduce the levothyroxine dosage 1.
Practical dose adjustment approach:
- For doses ≥200 mcg: reduce by 50 mcg 2
- For doses ≤175 mcg: reduce by 25 mcg 2
- Recheck TSH in 6-8 weeks 3, 4
The FDA label warns that overtreatment with levothyroxine may cause adverse cardiovascular effects including increased heart rate, cardiac wall thickness, arrhythmias, and may precipitate angina—particularly concerning in elderly patients 4. Long-term TSH suppression is also associated with increased fracture risk in women >65 years when TSH ≤0.1 mIU/L 1.
For Thyroid Cancer
Do not adjust the dose without consulting the treating endocrinologist 1. Many thyroid cancer patients require intentional TSH suppression to <0.1 mIU/L as part of their cancer management 5. The target TSH should be reviewed by the patient's specialist before making changes 1.
Key Pitfalls to Avoid
Never abruptly discontinue levothyroxine in patients with established hypothyroidism. The 2004 JAMA guidelines recommend dose reduction, not cessation 1. While recent research shows 25.7% of adults ≥60 years can successfully discontinue levothyroxine through gradual tapering 6, this requires a structured protocol with close monitoring—not acute cessation.
Check free T4 and T3 levels along with repeating TSH within 4 weeks 1. A suppressed TSH with normal free T4 confirms exogenous subclinical hyperthyroidism from overtreatment. However, you must exclude other causes of low TSH (central hypothyroidism, nonthyroidal illness) 1.
Consider patient-specific factors:
- Elderly patients and those with cardiac disease are at highest risk from TSH suppression and warrant more aggressive dose reduction 1
- Postmenopausal women face increased bone loss risk with chronic TSH suppression 1
- Patients taking doses ≤50 mcg/day are more likely to successfully discontinue if appropriate 6
Monitoring Strategy
After dose reduction:
- Recheck TSH in 6-8 weeks 3, 4
- Target TSH: 0.45-4.12 mIU/L for most adults 3
- Age-adjusted upper limits: 7 mIU/L for ages 70-79,8 mIU/L for >80 years 7
- Once stable, annual monitoring suffices 3
The French Endocrine Society recommends maintaining TSH >1 mIU/L in elderly patients to prevent iatrogenic thyrotoxicosis, which occurs in 20-50% when TSH remains suppressed 7.